157 reports of this reaction
1.6% of all LABETALOL HYDROCHLORIDE reports
#15 most reported adverse reaction
FOETAL EXPOSURE DURING PREGNANCY is the #15 most commonly reported adverse reaction for LABETALOL HYDROCHLORIDE, manufactured by Par Health USA, LLC. There are 157 FDA adverse event reports linking LABETALOL HYDROCHLORIDE to FOETAL EXPOSURE DURING PREGNANCY. This represents approximately 1.6% of all 9,779 adverse event reports for this drug.
Patients taking LABETALOL HYDROCHLORIDE who experience foetal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FOETAL EXPOSURE DURING PREGNANCY is a less commonly reported adverse event for LABETALOL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to foetal exposure during pregnancy, the following adverse reactions have been reported for LABETALOL HYDROCHLORIDE:
The following drugs have also been linked to foetal exposure during pregnancy in FDA adverse event reports:
FOETAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 157 FDA reports for LABETALOL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FOETAL EXPOSURE DURING PREGNANCY accounts for approximately 1.6% of all adverse event reports for LABETALOL HYDROCHLORIDE, making it a notable side effect.
If you experience foetal exposure during pregnancy while taking LABETALOL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.